iiinova — where your digital self keeps evolving

Veeru Kasi

@veerukasi.bsky.social

Director @BURSTUrology | Hunterian Professor 2021 | Consultant Urologist & Associate Prof @UCL @UCLH | Ed Board @IJSSurgery @BJUIJournal @EUPlatinum | Man Utd

Posts Replies Media

Reposted by Veeru Kasi

Prostate Cancer UK Professionals @prostateukprofs.bsky.social · 23/10/2025

[9/9] 📖 If you would like to learn more about why this research is so important for men with #ProstateCancer, you can read more about the project in our latest News & Views article: buff.ly/3QrafUP

Prostate Cancer UK icon of a man having an MRI scan.

011

Reposted by Veeru Kasi

Prostate Cancer UK Professionals @prostateukprofs.bsky.social · 23/10/2025

[8/9] Impact: 🥳 bpMRI detects clinically significant #ProstateCancer as effectively as mpMRI, without increasing detection of insignificant cancer. 💙 Adopting bpMRI scans would increase scanner capacity and help more men receive timely diagnoses.

A smiling man with lived experience spending time with his family, appearing happy and relaxed.

111

Reposted by Veeru Kasi

Prostate Cancer UK Professionals @prostateukprofs.bsky.social · 23/10/2025

[7/9] ✅ Importantly, the team also demonstrated that bpMRI and mpMRI detect a comparable number of clinically insignificant #ProstateCancer. 💙 This is crucial to minimise overdiagnosis and protect men from unnecessary biopsies.

Table showing that bpMRI and mpMRI detect a comparable number of clinically insignificant prostate cancer, with the difference in detection between the two methods being only −0.4%.

111

Reposted by Veeru Kasi

Prostate Cancer UK Professionals @prostateukprofs.bsky.social · 23/10/2025

[6/9] ✅ Excitingly, the research showed that bpMRI is just as effective as mpMRI in detecting clinically significant #ProstateCancer.

Graph showing that mpMRI detected slightly more clinically significant prostate cancer than bpMRI. Yet, the difference in detection between the two methods was only −0.4% and not statistically significant

111

Reposted by Veeru Kasi

Prostate Cancer UK Professionals @prostateukprofs.bsky.social · 23/10/2025

[5/9] 👨 In the trial, 490 men underwent a scan. 🩻 Results for bpMRI were reviewed first, followed by those for mpMRI. 💉 If either scan indicated #ProstateCancer, men had a targeted biopsy.

Diagram showing flow of participants in the PRIME Trial.

111

Reposted by Veeru Kasi

Prostate Cancer UK Professionals @prostateukprofs.bsky.social · 23/10/2025

[4/9] 💰 To explore this, we funded a clinical trial called PRIME, which investigated whether bpMRI is as effective as mpMRI in detecting clinically significant #ProstateCancer.

Quote from Associate Professor Veeru Kasivisvanathan, PRIME trial Lead Researcher and Chief Investigator: "If we can do the scan in up to half the time, with fewer staff and at a lower cost, that will make a huge difference in allowing every man who needs a scan to be able to get one in a timely fashion."

111

Reposted by Veeru Kasi

Prostate Cancer UK Professionals @prostateukprofs.bsky.social · 23/10/2025

[3/9] 💡 The team proposed biparametric MRI (bpMRI) as a faster, effective alternative. 🩻 While mpMRI uses 3 imaging types, bpMRI uses 2 and doesn’t require contrast agents, cutting scan time by up to 50%, increasing capacity, removing the need for injections, and lowering costs.

Advantages of biparametric MRI compared to multiparametric MRI include:
- Shorter Scans.
- Injection-free.
- Lower Cost.
- No medical practitioner required, as no contrast agent needed.
- Absence of contrast agent reduces environmental impact.

111

Reposted by Veeru Kasi

Prostate Cancer UK Professionals @prostateukprofs.bsky.social · 23/10/2025

[2/9] ️Multiparametric MRI (mpMRI) is now a key part of the diagnostic pathway for #ProstateCancer, thanks in part to research we supported in 2008. 👨 The next challenge: how can we make diagnostic imaging more efficient?

111

Reposted by Veeru Kasi

Prostate Cancer UK Professionals @prostateukprofs.bsky.social · 23/10/2025

[1/9] 🔎 Let’s take a closer look at the exciting findings from the Prostate Cancer UK-funded study led by @veerukasi.bsky.social, Dr Alex Ng & Dr Aqua Asif at @ucl.ac.uk recently published in @jama.com 🧵.

bsky.app

Prostate Cancer UK Professionals (@prostateukprofs.bsky.social)

121

Reposted by Veeru Kasi

Prostate Cancer UK Professionals @prostateukprofs.bsky.social · 16/09/2025

Could faster MRI scans allow more men to receive timely #ProstateCancer diagnoses? Research published in @jama.com led by @veerukasi.bsky.social, Dr Alex Ng & Dr Aqua Asif at @ucl.ac.uk compares the efficacy of shortened versus standard-length scans. Grab a ☕ & read: doi.org/10.1001/jama...

Scientific Paper Published in The Journal of the American Medical Association, titled: Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial. Written by Ng et al.

056

Reposted by Veeru Kasi

Prostate Cancer UK Professionals @prostateukprofs.bsky.social · 18/06/2025

[7/8] 🤗And the @ucl.ac.uk @veerukasi.bsky.social teams showed supporters how their fundraising is enabling huge improvements to diagnosis and care.

Dr Alex Ng, Dr Aqua Asif, Dr Hayley Luxton, Dr Alex Dudko, Dr Uzomamaka Okoli playing games and talking to supporters.

111

Reposted by Veeru Kasi

Aberdeen Centre for Evaluation (formerly HSRU) @ace-aberdeen.bsky.social · 22/05/2025

A huge thank you to all our collaborators for coming along to our #ELIPSE meeting @benchallacombe.bsky.social @veerukasi.bsky.social

021

Reposted by Veeru Kasi

BURSTurology @bursturology.bsky.social · 23/02/2025

📢 LESS THAN ONE WEEK LEFT "We welcome applications from a range of experience levels, from senior trainees to junior trainees to house officers or medical students" - Mr @veerukasi.bsky.social, BURST Director 🗓️ Apply by Feb 28th: redcap.slms.ucl.ac.uk/surveys/?s=3... #BURST10 #UroSoMe

022